05/16/12, Bayer HealthCare Pharmaceuticals
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session
more